ArticleEndocrinology2026
New insights into SREB orphan receptor roles in the ovary, using comparative transcriptomics across 3 fishes.
Article in Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Superconserved receptors expressed in brain (SREB) are a family of orphan G protein-coupled receptors with 3 members in most vertebrates (GPR27 or SREB1, GPR85 or SREB2, and GPR173 or SREB3). They are associated with diverse physiological processes, ranging from glucose homeostasis to ovarian development. Despite a lack of confirmed ligands, our understanding of these receptors has increased based on interactions with putative SREB3 ligands such as phoenixin (PNX) and the development of synthetic SREB1 agonists (A8535 and PT-91). However, to date no studies have used these agonists in any complex vertebrate system. The objective of this study was to compare the in vitro transcriptomic responses to PNX-20, A8535, and PT-91 in the ovaries of 3 fishes with different SREB systems: (1) zebrafish (Danio rerio) that exhibit similar receptors to mammals, (2) mummichog (Fundulus heteroclitus) that lost a receptor but gained a fish-specific member, and (3) pufferfish (Dichotomyctere nigroviridis) that exhibit all 4 receptors. Agonist interactions with fish SREB1s were confirmed using in silico characterizations. Zebrafish exhibited the strongest transcriptome response, including agonist-induced changes in oxidative phosphorylation and cell adhesion pathways. Mummichog exhibited a less robust response, possibly related to receptor evolutionary divergence, while pufferfish exhibited an intermediate transcriptome response. Short-term agonist exposure did not alter ovarian steroid levels ([17]estradiol, 17-hydroxyprogesterone, cortisol, testosterone, or 11-ketotestosterone). Collectively, the data reveal previously unrecognized developmental, metabolic, neural, and vascular gene networks associated with SREB activation and suggest both receptor-specific signaling and functional overlap within this family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.